We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

47 hedge funds and large institutions have $255M invested in Adaptimmune Therapeutics in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

228% more capital invested

Capital invested by funds: $77.9M → $255M (+$177M)

77% more call options, than puts

Call options by funds: $168K | Put options by funds: $95K

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

40% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 10

9% more funds holding

Funds holding: 43 → 47 (+4)

4.61% more ownership

Funds ownership: 10.32% → 14.93% (+4.6%)

Holders
47
Holders Change
+4
Holders Change %
+9.3%
% of All Funds
1.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
14
Reduced
10
Closed
9
Calls
$168K
Puts
$95K
Net Calls
+$73K
Net Calls Change
+$73K

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$41.6M
2
MCMC
Matrix Capital Management Company
New Hampshire
+$21.3M
3
BBA
Baker Bros. Advisors
New York
+$12.2M
4
Citadel Advisors
Citadel Advisors
Florida
+$6.81M
5
NMC
NEA Management Company
Maryland
+$4.15M

Top Sellers

Rank Fund Capital Flow
1
Man Group
Man Group
United Kingdom
-$3.49M
2
RG
Rathbones Group
United Kingdom
-$1.01M
3
TAM
TFG Asset Management
Cayman Islands
-$356K
4
GCP
GSA Capital Partners
United Kingdom
-$278K
5
MS
Maven Securities
Jersey
-$185K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
26
Panagora Asset Management
Massachusetts
$50K – – –
Invesco
27
Invesco
Georgia
$47K +$57.9K +17,448 New
Squarepoint
28
Squarepoint
New York
$34K +$41.7K +12,552 New
Qube Research & Technologies (QRT)
29
Qube Research & Technologies (QRT)
United Kingdom
$33K +$40.4K +12,167 New
TRCT
30
Tower Research Capital (TRC)
New York
$26K +$31.3K +9,429 +5,820%
Barclays
31
Barclays
United Kingdom
$20K +$22.8K +6,874 +1,307%
KBC Group
32
KBC Group
Belgium
$16K – – –
UBS Group
33
UBS Group
Switzerland
$14K -$3.79K -1,142 -18%
WAP
34
Wealthcare Advisory Partners
Pennsylvania
$8K +$10.1K +3,050 New
Simplex Trading
35
Simplex Trading
Illinois
$8K +$10.5K +3,150 New
Bank of America
36
Bank of America
North Carolina
$6K -$9.68K -2,917 -56%
Royal Bank of Canada
37
Royal Bank of Canada
Ontario, Canada
$6K -$3.68K -1,108 -36%
Citigroup
38
Citigroup
New York
$6K +$7.17K +2,162 +10,810%
Rockefeller Capital Management
39
Rockefeller Capital Management
New York
$5K – – –
US Bancorp
40
US Bancorp
Minnesota
$5K +$6.55K +1,973 New
LC
41
Lindbrook Capital
California
$3K +$3.11K +938 New
Osaic Holdings
42
Osaic Holdings
Arizona
$3K +$3.32K +1,000 New
PA
43
Parallel Advisors
California
$2K +$3.61K +1,087 New
NFG
44
Next Financial Group
Texas
$1K – – –
Wells Fargo
45
Wells Fargo
California
$1K – – –
ED
46
Exane Derivatives
France
$329 – – –
MS
47
Maven Securities
Jersey
– -$185K -150,000 Closed
Wellington Management Group
48
Wellington Management Group
Massachusetts
– -$100K -83,302 Closed
TCM
49
Tekla Capital Management
Massachusetts
– -$92K -77,061 Closed
HF
50
HRT Financial
New York
– -$53K -44,245 Closed
1
2
3

ADAP Hedge Fund Activity: Q1 2020 in Review

47 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2020, worth a combined $255M — up 228% from $77.9M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ADAP positions and 9 closed out — a net gain of 5 holders — while 14 added to existing stakes and 10 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $41.6M. The largest seller was Man Group, cutting an estimated $3.49M.

  • 47 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2020, up from 43 in Q4 2019.
  • Funds reported $255M of Adaptimmune Therapeutics stock for Q1 2020, up 228% quarter-over-quarter.
  • 14 funds opened new Adaptimmune Therapeutics positions in Q1 2020 and 9 closed out, a net change of +5 holders.
  • The largest Adaptimmune Therapeutics buyer in Q1 2020 was RA Capital Management, an estimated $41.6M added.
  • The largest Adaptimmune Therapeutics seller in Q1 2020 was Man Group, an estimated $3.49M sold.

Based on aggregated 13F filings for Q1 2020.